Harvard Bioscience, Inc. (HBIO)

In the past six months, Harvard Bioscience reported Q3 2025 EPS below forecast but exceeded revenue expectations, leading to a premarket stock decline. The company secured a $40 million credit facility agreement for debt refinancing. A strategic manufacturing consolidation was announced, including the closure of the Holliston plant, expected to generate cost savings. Harvard Bioscience filed for an offering of up to 9.5 million shares by selling stockholders. The Board of Directors approved an amendment to lower the quorum requirement for stockholder meetings. The company reported Q2 2025 EPS surpassing analysts' expectations.

While demand seasonality for Harvard Bioscience's products and services is suggested, specific patterns or detailed factors influencing this seasonality are not explicitly provided. The company's customer base could imply some correlation with academic funding cycles or research grant timelines. Concrete data on monthly or quarterly fluctuations in demand due to seasonal factors is not available.

Harvard Bioscience, Inc. is a global developer, manufacturer, and marketer of technologies, products, and services for life science applications. The company supports fundamental research, drug discovery, bioproduction, and preclinical testing for pharmaceutical and therapy development. Its product portfolio is categorized into Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology. Key products include cellular and molecular technology products, preclinical products, and software. Major brands include Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments.

Headquartered in Holliston, Massachusetts, Harvard Bioscience has an international presence with operations in North America, Europe, and China. The company directly markets its products in the US, the UK, Germany, France, Sweden, Canada, Italy, Spain, and China, and utilizes a network of distributors to reach customers in over 100 countries. Principal manufacturing facilities are located in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

Harvard Bioscience's stock performance has declined approximately 65.63% over the past year, indirectly affecting brand perception. The company has faced headwinds in academic research funding and uncertainty surrounding NIH funding and China tariffs. Despite these challenges, Harvard Bioscience positions itself as a trusted partner and a leading provider of lab equipment. Expanding its distribution agreement with Fisher Scientific and launching new products like VivaMARS and SoHo telemetry devices could bolster its reputation.

Harvard Bioscience, Inc. has 106 institutional owners and shareholders holding a total of 21,099,340 shares. Major institutional shareholders include AMH Equity Ltd, Weber Capital Management LLC ADV, Harvey Partners, LLC, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Acadian Asset Management Llc, Meros Investment Management, LP, Renaissance Technologies Llc, BlackRock, Inc., and Granahan Investment Management Inc/ma.